Abstract 192P
Background
Experimental and clinical studies have shown an increase in the level of interleukin-6 (IL-6) in the blood plasma and other cytokines in obstructive jaundice. The combination of a persistent increase in cytokines and an extended acute response phase is associated with a decrease in protein calories, leading to surgical complications and death.
Methods
The study involved 41 patients treated at the Gastroenterology department in 1st Republic Clinic, Tashkent aged from 33 to 84 years old (62.8 ± 2.14) were studied, of whom 26 (63.4%) were men and 15 (36.6%) were women. The duration of the icteric period by the time of admission to the hospital averaged 28.7 ± 2.18 days. At the same time, in 6 (14.6%) patients the duration of cholestasis was up to 15 days, in 10 (24.4%) - from 15 to 30 days, in 25 (61.0%) - more than 1 month. Percutaneous transhepatic cholangiography (PTCH) with per-cutaneous transhepatic cholangiostomy (PTCHS) was performed for all patients, regardless of the localization of the tumor process. The level of IL-6 in serum and bile was determined by ELISA method.
Results
The concentration of IL-6 before the overlap of PTCH in the serum was higher than normal, averaging 152.65 ± 16.3 pg/ml. Immediately after the overlaying of PTCH in bile, this indicator was on average 68.58 ± 7.24 pg/ml. The high content of IL-6 in serum and bile testified to a pronounced endogenous intoxication of the body. The concentration of IL-6 in the initial day after the imposition of PTCH in serum decreased to 32.9%. In the following days, this indicator remained virtually unchanged, but on the 6th day of observation, there was a slight increase in his blood. In the bile at the same time, the concentration of IL-6 decreased by 17.1%. These indicators remained virtually unchanged up to 6 days of observation. On the 14th day, the decrease in the level of IL-6 in the blood compared to baseline was 64.4%, and in the bile 54.3% (P < 0.001).
Conclusions
Thus, the determination of IL-6 in the blood and in the bile makes it possible to more objectively evaluate the tumor process and the cytokine-induced endogenous intoxication to the response of the therapeutic measures taken in biliopancreatoduodenal tumors complicated by the mechanical jaundice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract